Amniotic fluid epidermal growth factor concentrations. The effect of intra-amniotic thyroxine for acceleration of fetal maturation.
Intra-amniotic thyroxine (200-500 ug) was administered weekly to 29 women in the third trimester to enhance fetal maturation. Lecithin-sphingomyelin ratio (L/S) and epidermal growth factor (EGF) were measured in amniotic fluid (AF) before (n = 58) and after (n = 92) administration of thyroxine. The AF L/S ratio and EGF concentration increased linearly with increasing gestational age both before (r = 0.76, p < 0.0001; r = 0.41, p < 0.001, respectively) and after (r = 0.62, p < 0.0001; r = 0.43, p < 0.001 respectively) initiation of thyroxine treatment. The slopes of gestational age vs L/S (0.07) and EGF (0.004) before T4 increased significantly after initiation of T4 therapy (L/S:0.23, p < 0.001; EGF:0.015, p < 0.01, respectively). L/S ratios correlated with AF EGF levels before (r = 0.77, p < 0.001) and after (r = 0.63, p < 0.001) initiation of T4 therapy. These results demonstrate that intra-amniotic thyroxine accelerates not only the progression of the amniotic fluid L/S ratio, but the appearance of EGF.
Hofmann
G E
GE
Department of Obstetrics and Gynecology, Eastern Virginia Medical School, Norfolk.
Romaguera
J
J
Williams
R F
RF
Adamsons
K
K
Norfolk
V A
VA
San Juan
P R
PR
D000328:Adult; D000650:Amnion; D000653:Amniotic Fluid / Q000737:chemistry / Q000187:drug effects*; D005314:Embryonic and Fetal Development / Q000187:drug effects*; D004815:Epidermal Growth Factor / Q000032:analysis / Q000187:drug effects*; D005260:Female; D005325:Fetal Organ Maturity; D005865:Gestational Age; D006801:Humans; D007267:Injections; D008168:Lung / Q000187:drug effects* / Q000196:embryology; D010713:Phosphatidylcholines / Q000032:analysis; D011247:Pregnancy; D013109:Sphingomyelins / Q000032:analysis; D013974:Thyroxine / Q000494:pharmacology*
D010713:Phosphatidylcholines; D013109:Sphingomyelins; D004815:Epidermal Growth Factor; D013974:Thyroxine